tirzepatide and bimagrumab Combination plus semaglutide confers weight loss while preserving lean mass New drugs for the treatment

FDA in 2019, providing an alternative to injectable treatments for those who prefer oral administration

A meta-analysis showed that sulfonylurea use is associated with an increased risk of HCC, while GLP-1RAs can lower the risk of HCC (Wang et al., 2024)

Prioritize sleep quality and stress management to enhance the effectiveness of any weight loss intervention

It has been great for my gut and is actually improving some of my IBS symptoms, as for weight loss it's a little early to tell, but it has dramatically reduced my appetite, so we'll see

Conclusion The weight loss gap between retatrutide and semaglutide is real, mechanistically explained, and consistent across two Phase 3 trials